Pasithea Therapeutics Expands NF1 Trial Dosing, Extends Treatment Period for PAS-004
Summary
Pasithea Therapeutics has amended the protocol for its Phase 1/1b clinical trial of PAS-004 for NF1, adding higher dose levels up to 32mg and extending the treatment period to 18 months. These changes aim to gather more comprehensive data and optimize dose selection for future registrational studies. The company has already enrolled additional patients in new cohorts and remains on track to release interim NF1 data in Q4 2026. This strategic update strengthens the development path for their lead drug candidate.
At the time of this announcement, KTTA was trading at $0.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.7M. The 52-week trading range was $0.28 to $2.06. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.